rs2153960 — FOXO3

Intronic FOXO3 tag SNP whose A allele associates with higher circulating IGF-1 at genome-wide significance; the G allele may favor lower IGF-1 and stronger FOXO3 pathway activation

See your personal result for FOXO3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FOXO3's IGF-1 Regulatory Locus — The Signal Behind the Signal

FOXO3 encodes the most consistently replicated longevity gene in human genetics. But not every variant within FOXO3 is a longevity signal — and rs2153960 illustrates that distinction with unusual clarity. This intronic SNP does not itself associate with exceptional lifespan in large meta-analyses, yet it sits at a locus whose biological output — modulation of circulating insulin-like growth factor 1 (IGF-1) — is directly connected to how FOXO3 protein exerts its anti-aging effects. Understanding rs2153960 means understanding the IGF-1/FOXO3 axis that makes FOXO3 one of the most consequential longevity genes ever identified.

Kaplan et al. 201111 Kaplan et al. 2011
A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet. 2011 conducted a GWAS of 10,280 middle-aged and older adults from four community cohorts, finding a borderline genome-wide significant association between rs2153960 and serum IGF-1 concentration (p = 5.1 × 10⁻⁷), and noting that this locus was "associated with longevity." The signal was subsequently confirmed at full genome-wide significance in a larger meta-analysis of 30,884 European-ancestry adults across 21 studies, which explicitly described rs2153960 as "the known longevity-associated variant (FOXO3)" and highlighted it as evidence for "the IGF axis in mediating effects of known (FOXO3) and novel longevity-associated loci."

The Mechanism

The insulin/IGF-1 signaling (IIS) pathway is evolution's primary master regulator of lifespan across metazoans — the same pathway that extends lifespan in nematodes, flies, mice, and is associated with human longevity. FOXO3 sits at the nexus of this pathway: when IGF-1 levels are low, the PI3K-AKT cascade is inactive, FOXO3 remains unphosphorylated and translocates to the nucleus, where it activates hundreds of genes involved in oxidative stress resistance, DNA repair, autophagy, and controlled apoptosis of damaged cells. When IGF-1 is high, AKT phosphorylates FOXO3 and traps it in the cytoplasm, silencing its protective program.

rs2153960 lies in intron 2 of FOXO3, a 101,625 base-pair noncoding region that contains multiple independent regulatory elements. As an intronic variant with no confirmed functional characterization (unlike rs2802292, which has a demonstrated HSF1 binding site mechanism), rs2153960 likely tags a nearby regulatory element that influences either FOXO3 expression or a gene in the same chromatin domain. The A allele associates with higher circulating IGF-1 at genome-wide significance. Higher IGF-1 means more AKT activation, more FOXO3 nuclear exclusion, and attenuated longevity pathway activation — the opposite of what the established longevity-associated G alleles at rs2802292 and rs2764264 achieve.

The 22 GWAS Catalog records additional associations for rs2153960 including cortical thickness (G allele, p = 3 × 10⁻¹⁶) and subcortical brain volumes — associations likely reflecting LD with nearby FOXO3 regulatory variants that influence brain-expressed FOXO3 activity, consistent with FOXO3's documented role in neuronal stress resistance and cognitive aging.

The Evidence

The primary evidence for rs2153960 is metabolic, not longevity-specific. The FOXO3 locus as a whole is one of the most replicated longevity signals in human genetics — the rs280229233 rs2802292
the primary FOXO3 longevity variant with a characterized HSF1-binding mechanism variant has been replicated in every human population studied. rs2153960 tags this same locus but is a distinct regulatory signal: it is correlated with IGF-1 levels but is NOT the functional longevity variant itself.

Bao et al. 201444 Bao et al. 2014
Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014 examined 11 independent FOXO3 longevity studies and explicitly found "no association between rs2153960, rs7762395 or rs13220810 polymorphisms and longevity," while confirming associations for rs2802292, rs2764264, rs13217795, rs1935949, and rs2802288. This establishes rs2153960 as a metabolic biomarker variant at the FOXO3 locus rather than a direct longevity variant in its own right.

This distinction matters for interpretation. The variant's value is contextual: it captures variation in IGF-1 signaling tone that may modify how effectively FOXO3's protective mechanisms operate across decades. Notable population frequency differences — the A allele is common (~70%) in Europeans and East Asians but rare (~17%) in Africans — suggest this variant arose or rose to high frequency in non-African populations through mechanisms that may relate to historical differences in nutrition or growth environments, though this is speculative.

Practical Implications

For individuals carrying the AA or AG genotype (the common pattern in most non-African populations), the relevant consideration is that their FOXO3 locus may be tagging a higher-IGF-1 regulatory state. This makes lifestyle interventions that lower IGF-1 and directly activate FOXO3 especially relevant — caloric restriction, protein cycling (lower animal protein), and extended fasting all reliably reduce IGF-1 and restore FOXO3 nuclear access.

For GG carriers (the ancestrally enriched genotype, most common in individuals of African ancestry), the locus tags a lower-IGF-1 regulatory state that may represent better baseline FOXO3 activation capacity. This is consistent with the well-established principle in longevity biology that lower-normal IGF-1 (100–150 ng/mL) is associated with healthier aging trajectories.

In all cases, the evidence-based interventions for supporting FOXO3 signaling — fasting, plant-protein diets, resistance training, and HIIT — remain the most actionable tools, regardless of genotype at this locus.

Interactions

rs2153960 is located in the same 101,625 base-pair FOXO3 intron 2 that harbors rs2802292 (the primary longevity variant whose G allele creates an HSF1 binding site) and rs12212067 (the MZF1-binding anti-inflammatory variant). The mechanisms are distinct: rs2802292 adds a stress-activated enhancer, while rs2153960 tags IGF-1 regulatory capacity. Together, these provide a more complete picture of FOXO3 regulatory architecture than any single variant alone. Carriers who are GG at rs2153960 (lower IGF-1 tone) AND GG at rs2802292 (enhanced stress-response FOXO3 activation) would have the most favorable combined FOXO3 regulatory state.

The rs3576755 rs35767
IGF-1 promoter variant independently affecting IGF-1 transcription in the IGF1 gene itself provides complementary information about the IGF-1/FOXO3 axis from the ligand side; individuals with low-IGF-1 variants at both the IGF1 locus and the FOXO3 locus may have particularly robust FOXO3 pathway activation.

Genotype Interpretations

What each possible genotype means for this variant.

AA Common FOXO3 Locus Genotype Normal

Most common genotype — FOXO3 locus tagging higher-IGF-1 regulatory state

The AA genotype at rs2153960 represents the population-majority state in most non-African populations. The A allele associates with higher serum IGF-1 concentrations at the FOXO3 locus — not because rs2153960 itself is functional, but because it tags a regulatory element that influences the IGF-1 signaling tone at this genomic region. Elevated IGF-1 activates the PI3K-AKT signaling cascade, which phosphorylates FOXO3 at three serine/threonine residues, causing 14-3-3 protein binding and nuclear export. In the cytoplasm, FOXO3 cannot activate its transcriptional targets: antioxidant genes (catalase, MnSOD), DNA repair genes, autophagy regulators, and apoptosis mediators in damaged cells.

The practical consequence is subtle: the AA genotype doesn't impair FOXO3 function, it reflects a regulatory context where baseline FOXO3 nuclear residence may be somewhat lower than in GG carriers. Importantly, the Bao 2014 meta-analysis found NO direct longevity association for rs2153960 itself, so this variant's interpretation is probabilistic and contextual rather than clinically definitive. Lifestyle interventions remain highly effective at activating FOXO3 regardless of this genotype.

GG Lower IGF-1 FOXO3 Locus Beneficial

G homozygote — the ancestrally enriched FOXO3 locus genotype with lower IGF-1 regulatory tone

The GG genotype at rs2153960 reflects the ancestral human regulatory state at this FOXO3 locus, preserved at high frequency in populations of African ancestry (~70% GG). The G allele's association with lower IGF-1 aligns with the fundamental biology of the IIS pathway in longevity: reduced IGF-1 signaling → reduced AKT activation → reduced FOXO3 phosphorylation → more FOXO3 in the nucleus → stronger activation of antioxidant, DNA repair, autophagy, and cell quality control programs.

It is important to note that rs2153960 itself did NOT associate with exceptional longevity in the Bao 2014 meta-analysis of 11 studies, meaning this variant tags an IGF-1 regulatory advantage without directly translating to centenarian enrichment. The established longevity variants at this locus — rs2802292, rs2764264, rs1935949 — operate through distinct mechanisms (HSF1 binding, NKX3 repressor disruption, SRF enhancer activity) that have more direct evidence for lifespan extension. The GG genotype here provides a favorable metabolic background for FOXO3 activity rather than a primary longevity driver.

The GWAS associations with cortical thickness and brain morphology observed for the G allele (p = 3 × 10⁻¹⁶ for vertex-wise cortical thickness) may reflect FOXO3's role in neuronal stress resistance and brain maintenance across aging, consistent with FOXO3's documented neuroprotective functions.

AG Intermediate FOXO3 IGF-1 Profile Intermediate

One G allele — partial IGF-1 modulation at the FOXO3 locus

Heterozygous carriers at rs2153960 have one copy of each regulatory variant at this FOXO3 locus. The additive inheritance pattern for IGF-1 levels means AG individuals likely have intermediate IGF-1 concentrations compared to AA and GG homozygotes. This intermediate state is relevant because FOXO3 nuclear vs. cytoplasmic residence exists on a gradient — partial reduction in IGF-1 signaling means more FOXO3 can remain nuclear during periods of moderate (not maximal) growth factor stimulation.

The direct longevity association for rs2153960 AG heterozygotes has not been established in large centenarian studies, so the clinical interpretation of this genotype is primarily through the IGF-1 regulatory framework. The biological plausibility rests on the well-validated connection between lower IGF-1 signaling and healthier aging across model organisms and human populations with exceptional longevity.